Clinical trials: Renal Masses
Renal Cancer, Kidney Cancer
Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
The purpose of this study is to evaluate the blood flow in kidney masses by using ultrasound microbubble contrast material, and to see if results from ultrasound contrast studies can predict if a kidney mass is benign or…
- Trial name
- NCT00671411
- Testing
- Ultrasound with intravenous microbubble contrast injection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clear Cell Renal Cell Carcinoma
89Zr-DFO-girentuximab Expanded Access Program (EAP)
The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9…
- Trial name
- NCT06090331
- Testing
- 89Zr-DFO-girentuximab
- Where
- 22 sites in United States
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Small Renal Masses (SRM)
Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for Small Renal Masses
The execution of this study is pertinent to evaluating SBRT's short- and long-term efficacy and safety in the treatment of SRMs. This study will be the first to compare RFA and SBRT in the treatment of SRMs.
- Trial name
- SBRT vs RFA (NCT03811665)
- Testing
- Radiofrequency Ablation, Stereotactive body radiation therapy
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Renal Tumor, Renal Cell Carcinoma
PET/MR for Characterization of Renal Masses (RMs)
The frequency of kidney tumors found incidentally on imaging studies performed for unrelated reasons continues to increase leading to more surgeries and ablations for the treatment of renal masses thought to be cancer.
- Conditions
- Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
- Trial name
- NCT06076538
- Testing
- 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- University of Texas Southwestern Medical Center
Renal Cell Carcinoma, Renal Tumor
Non-Invasive Diagnostics of Small Renal Masses
NiSAR is a Ph.D. study and consists of three substudies. Renal cancer is one of the most deadly urologic malignancies and accounts for 900 new cases and 300 deaths per year.
- Trial name
- NISar (NCT03667885)
- Testing
- Blood sample, urine sample, Multi planar MRI
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Odense University Hospital
Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer
This phase I/II trial investigates the side effects of interstitial brachytherapy and to see how well it works in limiting the growth of large kidney cancer masses in patients with kidney cancer that have refused or are unable to…
- Trial name
- NCT04473781
- Testing
- Interstitial Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Kidney Cancer
Safety and Feasibility of IRE for SRMs
Irreversible Electroporation (IRE) is an emerging technique delivering electrical pulses to ablate tissue, with the theoretical advantage to overcome the main shortcomings of conventional thermal ablation.
- Trial name
- NCT02828709
- Testing
- Irreversible Electroporation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Dr. Prof. M.P. Laguna Pes
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON…
- Trial name
- NCT06750419
- Testing
- 89Zr-TLX250 PET/CT
- Where
- 8 sites in China
- Volunteers
- 82 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Complex Renal Cyst
Surveillance of Complex Renal Cysts - The SOCRATIC Study
One third of individuals aged >60 years will be diagnosed with at least one renal cyst following abdominal imaging. These cystic lesions are categorized according to the Bosniak classification which categorizes cysts according to…
- Trial name
- SOCRATIC (NCT04558593)
- Testing
- Active surveillance, Surgery
- Where
- 18 sites in Canada, France
- Volunteers
- 330 people
- Sponsor
- Université de Sherbrooke
Renal Cancer
Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients.
- Trial name
- NCT01888198
- Testing
- (EORTC QLQ-C30) questionnaire, EuroQol EQ-5D 7-item questionnaire
- Where
- 6 sites in United States
- Volunteers
- 294 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Carcinoma, Renal Mass
Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery
This clinical trial studies a type of ultrasound called robot-assisted laparoscopic high-intensity focused ultrasound for performing thermal ablative therapy, or sound wave therapy, in treating patients with small kidney masses…
- Trial name
- NCT02370342
- Testing
- Robot-Assisted Laparoscopic Surgery, High-Intensity Focused Ultrasound Ablation, Therapeutic Laparoscopic Surgery
- Where
- 2 sites in United States
- Sponsor
- University of Southern California
Clear Cell Renal Cell Carcinoma
68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
This is a prospective, single-center, single-arm, diagnostic phase 2 study in patients who have renal masses scheduled for surgical resection.
- Trial name
- NCT05879510
- Testing
- 68Ga-NY104 PET/CT
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Peking Union Medical College Hospital
Kidney Cancer
Protocol Active Surveillance Small Renal Masses (SRMs)
Prospective study of active surveillance, non-randomized, multicentric, in asymptomatic patients over the age of 50 years, not affected by other tumors, with occasional diagnosis of single monolateral solid renal mass equal to or…
- Trial name
- NCT03804320
- Testing
- Active Surveillance
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- IRCCS San Raffaele
Renal Cell Carcinoma, Kidney Cancer
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
- Trial name
- NCT00606632
- Testing
- 124-Iodine-cG250 (124I-cG250), CT
- Where
- 14 sites in United States
- Volunteers
- 226 people
- Sponsor
- Heidelberg Pharma AG
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma
Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese…
- Conditions
- Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer
- Trial name
- ZIRDOSE-CP (NCT05861778)
- Testing
- 89Zr-Girentuximab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Renal Cell Carcinoma
Efficacy of Ultrasound Contrast Agent to Assess Renal Masses
Patients with an incidentally discovered small renal masses (SRM) < 4 cm in diameter are included. All patients will undergo biopsy for tissue diagnosis. Most patients will be followed by imaging.
- Trial name
- NCT01062178
- Testing
- Definity
- Where
- Canada
- Volunteers
- 167 people
- Sponsor
- University Health Network, Toronto
Clear Cell Renal Cell Carcinoma (ccRCC)
Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM
68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT07768306
- Testing
- 68Ga-NYM096 injection
- Volunteers
- 20 people
- Sponsor
- Norroy Bioscience Co., LTD
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
- Trial name
- 89ZR-TLX250 (NCT03849118)
- Testing
- 89Zr-girentuximab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 300 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Patients With Newly Diagnosed Small Renal Masses(<4cm)
The Natural History of Small Renal Masses
There is a rising incidence of incidentally detected small renal tumours due to improved imaging techniques. Traditionally, patients diagnosed with these small renal masses undergo surgery and therefore there is limited data…
- Trial name
- NCT01305330
- Where
- Canada
- Volunteers
- 137 people
- Sponsor
- University Health Network, Toronto
Kidney Neoplasm
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, <=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to…
- Trial name
- DISSRM (NCT02346435)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine